Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity score-matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group.


Journal

BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 2 4 2020
medline: 1 12 2020
entrez: 2 4 2020
Statut: ppublish

Résumé

To compare outcomes of minimally invasive radical nephrectomy (MIS-RN) and robot-assisted partial nephrectomy (RAPN) in clinical T2a renal mass (cT2aRM). Retrospective, multicentre, propensity score-matched (PSM) comparison of RAPN and MIS-RN for cT2aRM (T2aN0M0). Cohorts were PSM for age, sex, body mass index, American Society of Anesthesiologists (ASA) class, clinical tumour size, and R.E.N.A.L. score using a 2:1 ratio for RN:PN. The primary outcome was disease-free survival (DFS). Secondary outcomes included overall survival (OS), complication rates, and de novo estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m In all, 648 patients (216 RAPN/432 MIS-RN) were matched. There were no significant differences in intraoperative complications (P = 0.478), Clavien-Dindo Grade ≥III complications (P = 0.063), and re-admissions (P = 0.238). The MVA revealed high ASA class (hazard ratio [HR] 2.7, P = 0.044) and sarcomatoid (HR 5.3, P = 0.001), but not surgery type (P = 0.601) to be associated with all-cause mortality. Increasing R.E.N.A.L. score (HR 1.31, P = 0.037), high tumour grade (HR 2.5, P = 0.043), and sarcomatoid (HR 2.8, P = 0.02) were associated with recurrence, but not surgery (P = 0.555). Increasing age (HR 1.1, P < 0.001) and RN (HR 3.9, P < 0.001) were predictors of de novo eGFR of <45 mL/min/1.73 m RAPN had similar oncological outcomes and morbidity profile as MIS-RN, while conferring functional benefit. RAPN may be considered as a first-line option for cT2aRM.

Identifiants

pubmed: 32232920
doi: 10.1111/bju.15064
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114-123

Subventions

Organisme : Stephen Wiessman Kidney Cancer Research Fund
ID : SUR8658
Pays : International

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.

Références

Ljungberg B, Albiges L, Abu-Ghanem Y et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2019 update. Eur Urol 2019; 75: 799-810
Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 2014; 65: 372-7
Campbell S, Uzzo RG, Allaf ME et al. Renal mass and localized renal cancer: AUA guideline. J Urol 2017; 198: 520-9
Pierorazio PM, Johnson MH, Patel HD et al. Management of renal masses and localized renal cancer: systematic review and meta-analysis. J Urol 2016; 196: 989-99
Ristau BT, Handorf EA, Cahn DB et al. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage 1b-2 renal masses: an analysis of the national cancer data base. Cancer 2018; 124: 3839-48
Kopp RP, Mehrazin R, Palazzi KL et al. Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. Nephrometry Score. BJU Int 2014; 114: 708-18
Breau RH, Crispen PL, Jimenez RE, Lohse CM, Blute ML, Leibovich BC. Outcome of stage T2 or Greater renal cell cancer treated with partial nephrectomy. J Urol 2010; 183: 903-8
Long CJ, Canter DJ, Kutikov A et al. Partial nephrectomy for renal masses ≥ 7 cm: technical, oncological and functional outcomes. BJU Int 2012; 109: 1450-6
Becker F, Roos FC, Janssen M et al. Short-term functional and oncologic outcomes of nephron-sparing surgery for renal tumours ≥7 cm. Eur Urol 2011; 59: 931-7
Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM Staging. J Urol 1999; 162: 1930-3
Bertolo RG, Zargar H, Autorino R et al. Estimated glomerular filtration rate, renal scan and volumetric assessment of the kidney before and after partial nephrectomy: a review of the current literature. Minerva Urol Nefrol 2017; 69: 539-47
Ukimura O, Haber GP, Remer EM, Gill IS. Laparoscopic partial nephrectomy for incidental stage pT2 or worse tumors. Urology 2006; 68: 976-82
Alanee S, Nutt M, Moore A et al. Partial nephrectomy for T2 renal masses: contemporary trends and oncologic efficacy. Int Urol Nephrol 2015; 47: 945-50
Shum CF, Bahler CD, Sundaram CP. Matched comparison between partial nephrectomy and radical nephrectomy for T2 N0 M0 tumors, a study based on the National Cancer Database. J Endourol 2017; 31: 800-5
Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A, Autorino R. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol 2017; 71: 606-17
Bertolo R, Autorino R, Simone G et al. Outcomes of robot-assisted partial nephrectomy for clinical T2 renal tumors: a multicenter analysis (ROSULA Collaborative Group). Eur Urol 2018; 74: 226-32
Malkoc E, Ramirez D, Kara O et al. Robotic and open partial nephrectomy for localized renal tumors larger than 7 cm: a single-center experience. World J Urol 2017; 35: 781-7
Delto JC, Paulucci D, Helbig MW et al. Robot-assisted partial nephrectomy for large renal masses: a multi-institutional series. BJU Int 2018; 121: 908-15
Stroup SP, Hamilton ZA, Marshall MT et al. Comparison of retroperitoneal and transperitoneal robotic partial nephrectomy for pentafecta perioperative and renal functional outcomes. World J Urol 2017; 35: 1721-8
Anele UA, Marchioni M, Yang B et al. Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA Collaborative Group). World J Urol 2019; 37: 2439-50
Donat SM, Diaz M, Bishoff JT et al. Follow-up for clinically localized renal neoplasms: AUA Guideline. J Urol 2013; 190: 407-16
Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12
Amin MB, Edge SB, Greene FL et al. eds. AJCC Cancer Staging Manual, 8th edn, New York, NY: Springer: 2017
Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009; 182: 844-53
Dindo D, Demartines N, Clavien PA Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-13
Hamilton ZA, Capitanio U, Risk Pruthi D et al. Factors for upstaging, recurrence, and mortality in clinical T1-2 renal cell carcinoma patients upstaged to pT3a disease: an international analysis utilizing the 8th edition of the Tumor-Node-Metastasis staging criteria. Urology 2019 [Epub ahead of print]. https://doi.org/10.1016/j.urology.2019.11.036
Derweesh IH, Ryan ST, Hamilton ZA. Partial nephrectomy for T1b and T2 renal masses: a subtle paradigm shift and a new synthesis. Cancer 2018; 124: 3798-801
Kopp RP, Liss MA, Mehrazin R et al. Analysis of renal functional outcomes after radical or partial nephrectomy for renal masses >7cm using the RENAL score. Urology 2015; 86: 312-9
Kambara T, Tanimoto R, Araki M et al. Renal function after nephrectomy influences the risk of cardiovascular events. Acta Med Okayama 2018; 72: 241-7
Wu J, Suk-Ouichai C, Don W et al. Analysis of survival for patients with chronic kidney disease primarily related to renal cancer surgery. BJU Int 2018; 121: 93-100
Hamilton ZA, Capitanio U, Lane BR et al. Should partial nephrectomy be considered "elective" in patients with stage 2 chronic kidney disease? A comparative analysis of functional and survival outcomes after radical and partial nephrectomy. World J Urol 2019; 37: 2429-37
Karellas ME, O'Brien MF, Jang TL, Bernstein M, Russo P. Partial nephrectomy for selected renal cortical tumours of ≥7 cm. BJU Int 2010; 106: 1484-7
Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG. Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. BJU Int 2007; 100: 1235-9
Jeldres C, Patard JJ, Capitanio U et al. Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristics. Urology 2009; 73: 1300-5
Ghali F, Elbakry AA, Hamilton ZA et al. Robotic partial nephrectomy for clinical T2a renal mass is associated with improved trifecta outcome compared to open partial nephrectomy: a single surgeon comparative analysis. World J Urol 2019 [Epub ahead of print]. https://doi.org/10.1007/s00345-019-02994-2

Auteurs

Aaron W Bradshaw (AW)

Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.

Riccardo Autorino (R)

Division of Urology, VCU Health System, Richmond, VA, USA.

Giuseppe Simone (G)

Department of Urology, IRCCS-"Regina Elena" National Cancer Institute, Rome, Italy.

Bo Yang (B)

Department of Urology, Changhai Hospital, Shanghai, China.

Robert G Uzzo (RG)

Division of Urology and Urologic Oncology, Fox Chase Cancer Center, Philadelphia, USA.

Francesco Porpiglia (F)

Department of Urology, University of Turin-San Luigi Gonzaga Hospital, Turin, Italy.

Umberto Capitanio (U)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

James Porter (J)

Swedish Urology Group, Seattle, WA, USA.

Riccardo Bertolo (R)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Andrea Minervini (A)

Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.

Clayton Lau (C)

Division of Urology and Urologic Oncology, City of Hope National Medical Center, Duarte, CA, USA.

Kenneth Jacobsohn (K)

Department of Urology, Medical College Wisconsin, Milwaukee, WI, USA.

Akbar Ashrafi (A)

Institute of Urology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

Daniel Eun (D)

Department of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.

Alexandre Mottrie (A)

Department of Urology, OLV Hospital, Aalst, Belgium.

Wesley M White (WM)

Department of Urology, University of Tennessee Medical Center, Knoxville, TN, USA.

Luigi Schips (L)

Department of Urology, SS Annunziata Hospital, "G.D'Annunzio" University of Chieti, Chieti, Italy.

Benjamin J Challacombe (BJ)

Urology Centre, Guy's and St Thomas's NHS Foundation Trust, London, UK.

Ottavio De Cobelli (O)

Division of Urology, European Institute of Oncology, Milan, Italy.

Carmen M Mir (CM)

Department of Urology, Fundacion Instituto Valenciano Oncologia, Valencia, Spain.

Alessandro Veccia (A)

Division of Urology, VCU Health System, Richmond, VA, USA.

Alessandro Larcher (A)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Alexander Kutikov (A)

Division of Urology and Urologic Oncology, Fox Chase Cancer Center, Philadelphia, USA.

Monish Aron (M)

Institute of Urology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

Prokar Dasgupta (P)

Urology Centre, Guy's and St Thomas's NHS Foundation Trust, London, UK.

Francesco Montorsi (F)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Inderbir S Gill (IS)

Institute of Urology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

Chandru P Sundaram (CP)

Department of Urology, Indiana University Health, Indianapolis, IN, USA.

Jihad Kaouk (J)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Ithaar H Derweesh (IH)

Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH